Chitosan-dextran sulphate nanocapsule drug delivery system as an effective therapeutic against intraphagosomal pathogen Salmonella

Gnanadhas, Divya Prakash; Thomas, Midhun Ben; Elango, Monalisha; Raichur, Ashok M.; Chakravortty, Dipshikha

doi:10.1093/jac/dkt252

Cited by 79 publications

(37 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although aminoglycosides are effective against many bacterial pathogens, they exert poor to no activity in treating intracellular bacterial infections caused by Chlamydia species (2,3), Staphylococcus aureus (4), Legionella pneumophila (5), and Salmonella enterica (6). To overcome this intrinsic problem, many approaches to increase the entry of aminoglycosides into host cells, including the use of liposomal (7) and chitosan (8) encapsulations, have been proposed.…”

mentioning

confidence: 99%

Sensitization of Intracellular Salmonella enterica Serovar Typhimurium to Aminoglycosides In Vitro and In Vivo by a Host-Targeted Antimicrobial Agent

Kulp

Chen

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

c Aminoglycosides exhibit relatively poor activity against intracellular Salmonella enterica serovar Typhimurium due to their low permeativity across eukaryotic cell membranes. Previously, we identified the unique ability of AR-12, a celecoxib-derived smallmolecule agent, to eradicate intracellular Salmonella Typhimurium in macrophages by facilitating autophagosome formation and suppressing Akt kinase signaling. In light of this unique mode of antibacterial action, we investigated the ability of AR-12 to sensitize intracellular Salmonella to aminoglycosides in macrophages and in an animal model. The antibacterial activities of AR-12 combined with various aminoglycosides, including streptomycin, kanamycin, gentamicin, and amikacin, against intracellular S. Typhimurium in murine RAW264.7 macrophages were assessed. Cells were infected with S. Typhimurium followed by treatment with AR-12 or individual aminoglycosides or with combinations for 24 h. The in vivo efficacies of AR-12, alone or in combination with gentamicin or amikacin, were also assessed by treating S. Typhimurium-infected BALB/c mice daily for 14 consecutive days. Exposure of S. Typhimurium-infected RAW264.7 cells to a combination of AR-12 with individual aminoglycosides led to a reduction in bacterial survival (P < 0.05), both intracellular and extracellular, that was greater than that seen with the aminoglycosides alone. This sensitizing effect, however, was not associated with increased aminoglycoside penetration into bacteria or macrophages. Moreover, daily intraperitoneal injection of AR-12 at 0.1 mg/kg of body weight significantly increased the in vivo efficacy of gentamicin and amikacin in prolonging the survival of S. Typhimurium-infected mice. These findings indicate that the unique ability of AR-12 to enhance the in vivo efficacy of aminoglycosides might have translational potential for efforts to develop novel strategies for the treatment of salmonellosis.

show abstract

mentioning

confidence: 99%

Sensitization of Intracellular Salmonella enterica Serovar Typhimurium to Aminoglycosides In Vitro and In Vivo by a Host-Targeted Antimicrobial Agent

Kulp

Chen

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Furthermore, our collaborator's work towards understanding the efficacy of Chitosan-dextran sulphate (CD) nanocapsules in delivering specific drugs against intracellular bacterial pathogens suggest that CD nanocapsules could effectively deliver specific antibiotics against intraphagosomal Salmonella leading to killing and clearing the pathogen [29]. These above findings along with other available evidences suggest that chitosan and chitosan derivatives seem to possess significant antimicrobial activity and potential drug delivering system.…”

Section: Antimicrobial Propertymentioning

confidence: 94%

Chitosan Nanoparticles for Generating Novel Systems for Better Applications: A Review

G¹,

KS²

2015

J Mol Genet Med

View full text Add to dashboard Cite

The environmental sustainability and use of environmentally acceptable biomaterials are major areas of scientific and industrial research. In recent times, identification and application of suitable biopolymers instead of petroleum derived conventional polymers are gaining more attention. Chitosan and chitosan derived nanoparticles and nanocomposites are very promising due to their versatile properties and have found applications in various areas such as biomedical, foods, food packaging and personal care. Many studies suggest that chitosan nanoparticles and their derivatives are one of the best barrier and film coating materials for preserving the quality of foods and for delivering skin care products, mainly due to their biodegradability and anti-microbial properties. The present review gives insight on the progress made in the application of chitosan nanoparticles specifically in foods and food packaging, personal care products and in biomedical industry. Future studies shall address establishment of industrial scale up of chitosan nanoparticles, safety and quality aspects of these chitosan derived products for human use.

show abstract

“…Ideally, the NCs should not release their cargo before being internalized inside the cells where they should rapidly release the antimicrobial agents. Release inside cells is challenging to be studied and it should be kept in mind that it can be sometimes slower as compared with extracellular release [66]. NC excretion from cells and the associated mechanisms have been less studied than the cellular uptake mechanisms.…”

Section: Nanoparticulate Drug Delivery Systems and Their Internalizatiomentioning

confidence: 99%

“…Peritoneal macrophages Cephalothin Liposomes 1983 [102,103] Ampicillin Nanoparticles 1994 [104] 1994 [105] Chitosan 1996 [106] RAW 264.7, intestine 407 cells Ciprofloxacin Nanocapsules 2012 [107] Murine macrophage-like J774A.1 Gentamicin Liposomes 2013 [66] 1998 [65] Salmonella enterica Infected liver and spleen in a murine salmonellosis model Gentamicin Liposomes 2000 [108] J774A.1 macrophage cells Gentamicin Polymer complexes 2009 [109] Listeria monocytogenes Neutrophils Cloxacillin Liposomes 1986 [110] Human THP-1 cells, murine J 774 cells Gentamicin Nanoparticles 2010 [11] Peritoneal macrophages Ampicillin Liposomes 1988 [111] Nanoparticles 1992 [112] Escherichia coli Peritoneal macrophages Streptomycin Liposomes 1983 [113] Brucella abortus Mononuclear leukocytes Gentamicin Liposomes 1985 [114] Peritoneal macrophages 1985 [115] J 774 cells Nanoparticles 1996 [116] J 774 cells 2012 [117] THP-1 cells Micelles 2012 [118] Brucella melitensis THP-1 human monocytes Gentamicin Micro and nanoparticles 2006 [119] Candida albicans Murine peritoneal macrophages Amphotericin Liposomes 1998 [120] Chlamydia trachomatis and Chlamydia pneumoniae HEp2 cells Rifampin, azithromycin Nanoparticles 2011 [121] Toward an optimized treatment of intracellular bacterial infections Review higher with inhaled microparticles as compared with free drugs administered orally or by intracardiac injection.…”

Section: Salmonella Typhimuriummentioning

confidence: 99%

Toward an Optimized Treatment of Intracellular Bacterial Infections: Input of Nanoparticulate Drug Delivery Systems

Ladavière

Gref

2015

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Intracellular pathogenic bacteria can lead to some of the most life-threatening infections. By evolving a number of ingenious mechanisms, these bacteria have the ability to invade, colonize and survive in the host cells in active or latent forms over prolonged period of time. A variety of nanoparticulate systems have been developed to optimize the delivery of antibiotics. Main advantages of nanoparticulate systems as compared with free drugs are an efficient drug encapsulation, protection from inactivation, targeting infection sites and the possibility to deliver drugs by overcoming cellular barriers. Nevertheless, despite the great progresses in treating intracellular infections using nanoparticulate carriers, some challenges still remain, such as targeting cellular subcompartments with bacteria and delivering synergistic drug combinations. Engineered nanoparticles should allow controlling drug release both inside cells and within the extracellular space before reaching the target cells.

show abstract

Chitosan-dextran sulphate nanocapsule drug delivery system as an effective therapeutic against intraphagosomal pathogen Salmonella

Abstract: CD nanocapsules can be used as an efficient drug delivery system to treat intraphagosomal pathogens, especially Salmonella infection. This delivery system might be used effectively for other vacuolar pathogens including Mycobacteria, Brucella and Legionella.

Cited by 79 publications

References 37 publications

Sensitization of Intracellular Salmonella enterica Serovar Typhimurium to Aminoglycosides In Vitro and In Vivo by a Host-Targeted Antimicrobial Agent

Sensitization of Intracellular Salmonella enterica Serovar Typhimurium to Aminoglycosides In Vitro and In Vivo by a Host-Targeted Antimicrobial Agent

Chitosan Nanoparticles for Generating Novel Systems for Better Applications: A Review

Toward an Optimized Treatment of Intracellular Bacterial Infections: Input of Nanoparticulate Drug Delivery Systems

Contact Info

Product

Resources

About